MedTrace Logo

Study of Pomaglumetad and Methamphetamine

NCT03106571 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2020-09-01

No results posted yet for this study

Summary

This is the first study of pomaglumetad in humans using methamphetamine. The goal of the study is to determine if pomaglumetad is safe when administered with methamphetamine. If shown to be safe with methamphetamine in the current study, a phase 2 clinical trial of pomaglumetad would be done to begin to find out if pomaglumetad is effective in treating methamphetamine use disorder.

Conditions

  • Methamphetamine Use Disorder

Interventions

DRUG

Pomaglumetad methionil

Tablets twice daily

DRUG

Placebo

1-4 tablets twice daily

DRUG

Methamphetamine

intravenous methamphetamine

Sponsors & Collaborators

Principal Investigators

  • Keith Heinzerling, MD · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2020-07-31
Completion
2020-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03106571 on ClinicalTrials.gov